HOME > Press release

We wish to inform you that law no. 196/03 protects people
and other subjects as concerns the use of personal details.
Edit email address
Invialid email
Email Sent
Accept privacy law
 
TRIBUTE study shows superiority of Chiesi’s Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi completed a long-term clinical study with its extrafine fixed-dose triple combination inhaler (Trimbow®) in a single pressurised metered dose inhaler (pMDI) for COPD patients. Trimbow...
1/11
ARCHIVE PRESS RELEASE
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
Chiesi Farmaceutici is the first company to submit a marketing authorisation application to the European Medicine Agency for a Triple Combination for the treatment of COPD
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study
Patients with COPD benefit from the Chiesi extrafine fixed triple combination ICS/LABA/LAMA: highly effective and easy to use.
An extrafine ICS/LABA combination decreases COPD exacerbations more than
Chiesi To Acquire 3 Hospital Products
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
Europe approves Holoclar®, the first stem cell—based medicinal product
Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement For a Merger Transaction
PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY